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Abstract
Introduction: Clinical and laboratory studies demonstrate 
that placebo and nocebo effects influence various symp-
toms and conditions after the administration of both inert 
and active treatments. Objective: There is an increasing 
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need for up-to-date recommendations on how to inform pa-
tients about placebo and nocebo effects in clinical practice 
and train clinicians how to disclose this information. Meth-
ods: Based on previous clinical recommendations concern-
ing placebo and nocebo effects, a 3-step, invitation-only Del-
phi study was conducted among an interdisciplinary group 
of internationally recognized experts. The study consisted of 
open- and closed-ended survey questions followed by a final 
expert meeting. The surveys were subdivided into 3 parts: (1) 
informing patients about placebo effects, (2) informing pa-
tients about nocebo effects, and (3) training clinicians how 
to communicate this information to the patients. Results: 
There was consensus that communicating general informa-
tion about placebo and nocebo effects to patients (e.g., ex-
plaining their role in treatment) could be beneficial, but that 
such information needs to be adjusted to match the specific 
clinical context (e.g., condition and treatment). Experts also 
agreed that training clinicians to communicate about pla-
cebo and nocebo effects should be a regular and integrated 
part of medical education that makes use of multiple for-
mats, including face-to-face and online modalities. Conclu-
sions: The current 3-step Delphi study provides consensus-
based recommendations and practical considerations for 
disclosures about placebo and nocebo effects in clinical 
practice. Future research is needed on how to optimally tai-
lor information to specific clinical conditions and patients’ 
needs, and on developing standardized disclosure training 
modules for clinicians. © 2020 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Placebo and nocebo effects can substantially modulate 
the efficacy and tolerability of medical and psychological 
interventions for many symptoms and conditions [1–3]. 
Placebo and nocebo effects refer to favorable or adverse 
effects, respectively, that can arise as part of an active or 
inert intervention due to factors such as what the patient 
expects, the patient-clinician relationship, and other con-
textual factors [4–9]. These effects can be clinically mean-
ingful, with effect sizes for some conditions approaching 
treatment effect sizes [10]. Placebo effects can be shaped 
by a wide range of factors relating to medical practice, e.g., 
verbal suggestions made by the clinician, nonverbal cues 
in the patient-clinician interaction, or situational factors 
in the health care environment [11–16]. Differing view-
points as to how these effects should be handled exist, e.g., 
they are often seen as a nuisance in randomized con-
trolled trials as they complicate the testing of new drugs 
and therapies [17, 18]. On the other hand, there are po-
tential benefits of utilizing placebo effects to boost treat-
ment effects in clinical practice that have been recognized 
[16, 19, 20], although there is a variety of proposed ap-
proaches. Moreover, some caution in utilizing the mech-
anisms of placebo effects in clinical practice may be pru-
dent, as unforeseen adverse consequences (e.g., violation 
of expectation and loss of trust) may occur when effects 
are inadequately explained or elicited by deception (e.g., 
[21–23]). 
Due to these controversies, only a few ideas have been 
generated on how knowledge about placebo and nocebo 
effects should be translated into clinical practice [20]. For 
example, there are not many national guidelines about 
the use of placebo effects in medical practice [8], and they 
typically do not provide concrete clinical recommenda-
tions on how to optimize care by maximizing placebo and 
minimizing nocebo effects in clinical practice [24, 25]. It 
is also important to clearly distinguish between the de-
ceptive use of inactive placebo treatments in clinical prac-
tice, which is not recommended, and the systematic use 
of the mechanisms underlying placebo and nocebo effects 
to enhance standard treatments in an open way. When 
considering the potentially wide application of placebo 
and nocebo effects across health care, there is a need for 
recommendations on how to communicate about them 
(e.g., during patient-clinician interactions) to optimize 
patient outcomes. 
As a preliminary step, we provided consensus on the 
use of placebo and nocebo effects in clinical practice as 
part of the first official conference of the Society for In-
terdisciplinary Placebo Studies (SIPS) (https://www.pla-
cebosociety.org) [20]. This paper describes a follow-up to 
the previous recommendations [20] by collecting expert 
opinion on what should be communicated to patients 
about placebo and nocebo effects, and how clinicians 
should be trained to communicate about these topics in 
the context of medical patient-clinician interactions. 
Materials and Methods
A modified Delphi study was organized for a panel of interdis-
ciplinary experts by invitation (i.e., the speakers invited to partici-
pate at the 2019 SIPS conference) [26–28]. 
Expert Group
Twenty-seven internationally recognized and interprofession-
al placebo researchers took part in the panel, 67% of whom worked 
clinically (39% physicians, 56% psychologists, and 5% other, e.g., 
acupuncturists). Their backgrounds included anesthesiology, neu-
rology, cognitive neuroscience, primary care, internal medicine, 
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health and medical psychology, clinical psychology, psychological 
medicine, science communication, sports science, sociology, epi-
demiology, ethics, and philosophy. 
Modified Delphi Study
Input for the Delphi study was derived from the existing litera-
ture [20]. An open-ended survey was used to generate content for 
expert consensus on informing patients about placebo and nocebo 
effects in clinical practice (e.g., what, when, and how should we 
communicate about these effects?), and how clinicians should be 
trained to communicate about placebo and nocebo effects. An-
swers were transcribed verbatim and aggregated into 158 individ-
ual items ranked on a scale of 0–10 (0 = totally disagree; 10 = to-
tally agree) in round 2. Means and SD were calculated for each 
item. During round 3 (a preconference face-to-face clinical expert 
meeting, added to facilitate a nuanced discussion of possibly dif-
fering opinions on survey items), items with high agreement were 
discussed as input for the recommendations. More details on the 
methods used can be found in the online supplementary Material 
(see www.karger.com/doi/10.1159/000510738 for all online suppl. 
material).
Results
In the sections below and in Figure 1, we briefly de-
scribe the results of the Delphi study. The main recom-
mendations are listed in Table 1. 
Delphi Parts A & B:
Informing patients about placebo and nocebo effects
Message should cover:
• General information about placebo and nocebo effects
• An outline of the neurobiological & psychological mechanisms
• Information on the limits of placebo effects
Stipulations placed on 
informing: 
• Be evidence-based
• Do not overstate the scale of 
placebo effects
• Tailor to individual situations
Placebo effects Nocebo effects
Check need for informing
Stipulations placed on 
informing:
• Do not inform in a manner that
blames patients for negative
effects
• Avoid inducing anxiety
• Present information so that 
nocebo effects are minimized
• Be evidence-based
• Tailor to individual situations
Manner of informing:
Terminology
• Use ‘placebo effects’ (but explain carefully)
• Use ‘nocebo effects’ (but distinguish actual nocebo effects from adverse
events)
• Adopt additional terminology to explain the mechanisms
Methodology:
• Not one method (information letter, consult, online information) is
preferred over the other
Fig. 1. Schematic overview of the consider-
ations and the content of information 
needed for informing patients about pla-
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Informing Patients about Placebo and Nocebo Effects 
Based on the broad evidence for placebo and nocebo 
effects in clinical, neurobiological, and laboratory out-
comes [5–7, 19, 22, 29–39], the experts agreed that pla-
cebo and nocebo effects should be explained, and that pa-
tients should receive at least general information about 
these effects. Providing an outline of the neurobiological 
and psychological mechanisms could also be helpful, as 
could informing patients about the limits of placebo ef-
fects (e.g., placebo effects are likely to affect symptoms but 
not the progression of a disease) [40]. The experts recom-
mended placing several stipulations on informing pa-
tients about placebo and nocebo effects, e.g., information 
must be evidence-based and should not overstate the size 
of placebo effects. For both placebo and nocebo effects, 
the experts agreed that the information should be tailored 
to specific patients, conditions, and circumstances. For 
nocebo effects, this need was particularly emphasized, as 
a consequence of a delicate balance between following the 
ethics guidelines of informed consent (according to which 
patients need to be fully informed about risks and side ef-
fects of treatments as well as the possibility of treatment 
failures) and simultaneously preventing and reducing 
nocebo effects as much as possible [40–42]. Moreover, for 
nocebo effects, the need for informing should be consid-
ered, and, when deemed necessary, such disclosures 
should be made carefully in a manner that does not in-
crease anxiety and is not perceived as blaming patients for 
negative treatment effects (i.e., side effects). Information 
should, moreover, be presented in a way that minimizes 
nocebo effects. 
Regarding terminology, it was agreed that using the 
terms “placebo effect” and “nocebo effect” is acceptable, 
provided they are explained carefully, and that actual no-
cebo effects be distinguished from adverse events. When 
explaining the mechanisms involved, or if information is 
difficult for a patient to understand, clinicians may con-
sider using slightly different terminology (e.g., classical 
conditioning or response expectancy). Regarding the 
manner of informing, no one method (information leaf-
let, consultation, or online information) was preferred 
over the others. 
Training Clinicians in Communicating about Placebo 
and Nocebo Effects
Next to substantive information about placebo and 
nocebo effects (e.g., mechanisms, neurobiological and 
physiological underpinnings, variations in effect sizes 
and duration of effects, and that placebo effects can also 
work when people know about the effect), the experts 
agreed that clinicians should be taught about the relevant 
ethical issues concerning placebo and nocebo effects. 
Table 1. Main recommendations formulated by the expert group for communicating information about placebo and nocebo effects
Informing patients about placebo and nocebo effects
1 Patients should be informed that placebo effects are beneficial effects, represent a genuine reaction of the body that promotes healing and 
treatment response, are inherent to any treatment, and that anyone can experience them
2 Patients should be informed about the potential role of nocebo effects in increasing adverse effects
3 Patients should receive information about the underlying psychological and neurobiological mechanisms of placebo and nocebo effects, such as 
associative learning and expectations
4 Information provided to patients about placebo and nocebo effects should be evidence-based and not overstate the scale of placebo effects. When 
informing about nocebo effects, care should be taken to avoid inadvertently eliciting iatrogeny
5 How patients are informed about placebo and nocebo effects should be tailored to specific circumstances, patients, and health care context
6 When informing patients, the terms placebo effect and nocebo effect as well as related terms to explain the mechanisms (e.g., expectations, trust, 
and fear of side effects) should be used
Training clinicians to communicate about placebo and nocebo effects
7 Training of clinicians to communicate about placebo and nocebo effects should include an outline of the effects and clinical implications of both 
placebo and nocebo effects for different conditions as well as the underlying neurobiological and psychological mechanisms
8 Training should emphasize the need for tailoring information to the specific needs of individual patients, the type of treatment and the context in 
which it is offered, incorporating ethical considerations regarding informing patients about placebo and nocebo effects
9 Training should emphasize what clinicians can do to maximize placebo effects and minimize nocebo effects
10 Training should make use of different formats to inform clinicians about placebo and nocebo effects (e.g., face-to-face, online assignments, and 
written information)
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Effects in Clinical Practice
5Psychother Psychosom
DOI: 10.1159/000510738
Training could, moreover, emphasize that different pa-
tients might require different information, and that pla-
cebo and nocebo effects can operate differently for differ-
ent conditions. Finally, an emphasis should be placed on 
what clinicians can do to maximize placebo effects and 
minimize nocebo effects (i.e., deploying strategies such as 
optimizing verbal and nonverbal communication [15, 
30–33, 43–52]). 
As to the content of training, the experts agreed that it 
may be useful to use both general modules as well as mod-
ules relevant to specific medical conditions or specialists. 
They agreed that medical ethics education regarding pla-
cebo and nocebo effects should be a routine part of clini-
cal training. Training should preferably be embedded in 
a medical school or other standard education. However, 
the experts concluded during the meeting that more re-
search is needed and that empirical testing of the efficacy 
of training methods is essential.
More details on the Delphi results can be found in the 
online supplementary Material.
Discussion
This paper supplies the most up-to-date consensus-
based recommendation for communicating information 
about placebo and nocebo effects in clinical practice (Ta-
ble 1). The recommendations can support clinicians in 
their communications with their patients about placebo 
and nocebo effects.
The results reflect several established and emerging 
strands of literature in this area. For example, the need to 
communicate about side effects in ways that do not in-
duce nocebo effects is gaining more widespread recogni-
tion [30, 32, 53–58]. Because of ethical considerations 
[40, 41], tailoring information seems to be particularly 
imperative for nocebo effects, especially for those patients 
who may have a high risk of developing these effects [30–
32, 43, 53, 59]. The consensus on communicating infor-
mation about mechanisms is also reflected in studies 
showing that understanding the mechanisms of placebo 
effects may help to maximize these effects in clinical prac-
tice [2, 20, 42, 60–62]. 
The results showed a relatively high agreement among 
the experts that patients should receive general informa-
tion about placebo and nocebo effects. This includes con-
sensus that the inherent role of these effects in any treat-
ment should be explained, as should related mechanisms 
like the patient-clinician relationship, but also that this 
information needs to be adjusted to the specific context 
(e.g., the characteristics of the patients, the condition in 
question, and the treatment). For the latter recommenda-
tion, the need for careful consideration by the clinician on 
when and how to communicate information about pla-
cebo and nocebo effects should be recognized. This need 
is partly reflected in the consensus that, for instance, in-
formation should be evidence-based and presented with-
out overstating the scale of placebo effects. Overselling 
placebo effects may cause a violation of expectations 
when these are too high, thereby eroding trust in health 
care professionals, which, in turn, may lead to other neg-
ative consequences such as disengagement/nonadher-
ence with care (e.g., [21–23]). It is important to empha-
size that placebo effects can help optimize treatment out-
comes but that they cannot cure disease.
Moreover, clinicians may want to appraise what infor-
mation is appropriate for each individual patient, and ex-
ercise restraint when the benefit of supplying information 
to a patient is questionable. Care should be taken to not 
inadvertently elicit iatrogeny, i.e., unintended negative 
outcomes due to treatment [63–65]. This is a complex is-
sue, where a difficult balance exists between having to in-
form a patient of the potential side effects of treatment 
and not causing too much alarm [65]. When done appro-
priately, informing patients about placebo and nocebo ef-
fects may help enhance naturally occurring placebo ef-
fects in clinical practice and can even boost the efficacy of 
a treatment while simultaneously reducing nocebo ef-
fects. 
The Delphi method has several advantages: it offers 
rapid consensus and a wide range of expertise can be in-
cluded, while a socially desirable response due to group 
pressure is minimized. However, the methodology is not 
without limitations [26–28]. For example, the biases of 
the group (who all focus on studying placebos) may have 
influenced item selection. Also, some panel members 
may have been more outspoken than others during group 
discussions. It was nevertheless possible to reach consen-
sus regarding the main recommendations for informing 
patients and training health professionals.
The recommendations may not encompass all nuanc-
es that are typically found in placebo research. For ex-
ample, it is recommended that general mechanisms are 
explained, but no recommendations are provided about 
interactions of these mechanisms with other treatment 
factors. Another limitation is that some topics may have 
been overlooked. Additionally, these guidelines may not 
be generalizable to nonmedical contexts, such as physical 
therapy, psychotherapy, or treatments for which the role 
of placebo and nocebo effects has not yet been illustrated. 
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It should also be noted that the recommendations do not 
legitimize any form of nonevidence-based treatment, nor 
are we suggesting that proven therapies should be re-
placed with placebo treatments [66, 67]. Our method also 
did not allow us to draw conclusions about specific strat-
egies that can maximize placebo effects and minimize no-
cebo effects for a range of different conditions and con-
texts. Although we acknowledge their likely importance, 
we also did not focus on sociodemographic, cultural, per-
sonality, or genetic differences between patients in view 
of the limited existing evidence for subgroups of placebo 
and nocebo responders [68–70]. For example, there is 
emerging evidence that specific genotypes (e.g., [5, 71–
73]) may be associated with variation in the scale of pla-
cebo and nocebo effects, but there is not yet enough evi-
dence to include these findings in clinical recommenda-
tions.
Methodologically well-conducted replication studies 
that support the external validity of our findings are need-
ed for all these areas. Finally, the consensus described 
here should only be seen as hypothesis-generating. As a 
consequence, the experts emphasized the need for re-
search focusing on tailoring information to different pa-
tients and contexts, and developing evidence-based 
methods for training clinicians to communicate about 
placebo and nocebo effects. 
This study, based on a 3-stage Delphi approach, is an 
important step forward towards consensus-based recom-
mendations for communicating about placebo and no-
cebo effects in medical practice. The experts agreed that 
patients should receive general information about the 
mechanisms and neurobiology of placebo and nocebo ef-
fects, but that care should be taken to adjust this informa-
tion to the specific needs of patients and the treatment 
context. Multimodal training in communication about 
placebo and nocebo effects should be a regular and inte-
grated part of medical training for clinicians. The experts 
acknowledged the need for future research to expand 
knowledge about how best to provide information to pa-
tients, and about how clinicians can communicate about 
placebo and nocebo effects in the course of a treatment. 
Finally, implementation strategies should be developed 
to integrate these recommendations into clinical practice 
and the routine training and education of clinicians.
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